SMARCB1 and central nervous system cancer: Compared with the pcDNA3.1 group, SMARCB1 protein and mRNA expression levels were distinctly increased in the pcDNA3.1-SMARCB1 group, while it was clearly decreased in the SMARCB1 inhibitor group in comparison with that in the inhibitor NC group (P < 0.01) (Figures 3(a) and 3(b)), indicating that the cell transfection achieved high transfection efficiency of SMARCB1 overexpression and silencing in glioma cells.